Ian Mortimer
President, CEO, Principal Accounting Officer & Director
Good morning, everybody, and thanks for becoming a member of us. We’re excited to be talking with you recent off a extremely profitable American Epilepsy Society Assembly for Xenon. Earlier than we start, please be aware the usual discover that we’ll make numerous statements right now which are forward-looking. I encourage you to overview our SEC filings for a extra full dialogue of dangers going through our enterprise and readers are cautioned to not place undue reliance on such forward-looking statements.
After right now’s name, a recording of this presentation will probably be accessible on the Traders part of our web site at xenon-pharma.com. So becoming a member of me on right now’s name are Dr. Chris Kenney, our Chief Medical Officer; Darren Cline, our Chief Industrial Officer; and Tucker Kelly, our Chief Monetary Officer. I’ll begin right now with some opening remarks, together with an summary of our presence on the latest assembly of the American Epilepsy Society. And what we heard from clinicians concerning the alternative for azetukalner to meaningfully change the epilepsy therapy paradigm. Chris will then present an summary of the info we offered on the assembly, together with our newest X-TOLE open-label extension research knowledge. Then Darren will present an preliminary replace on the progress we’re making to organize for our first business launch. Tucker will then be part of us for a brief Q&A portion of the decision. As a reminder, if you would like to ask a query, you’ll be able to sort it into the chat field at any time. So let’s get began.
